Govt to aid development of India's 1st indigenous thrombectomy device for stroke care
The board sanctioned assistance to Mysuru-based S3V Vascular Technologies' pioneering neuro-intervention integrated manufacturing plant for the treatment of stroke, which sees nearly 1.5 million cases every year in the country.
The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam in Chennai's Sriperumbudur.
The plant will develop and manufacture advanced mechanical thrombectomy kits -- a life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion.
Compared to conventional thrombolysis, thrombectomy offers significantly improved outcomes, reducing the risk of long-term paralysis and disability.
"The TDB is proud to support S3V's vision of building India's first comprehensive neuro-intervention manufacturing ecosystem. This project reflects our continued commitment to making India a global hub for affordable, high-end medical technology -- especially in areas of critical public health needs like stroke care," TDB Secretary Rajesh Kumar Pathak said.
"The company's focus on integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare access," he added.
The initiative will help replace expensive imported devices with high-quality, locally manufactured alternatives, enhancing both the affordability and accessibility of stroke care in India.
"Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy but also reduces India's dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices," S3V Vascular Technologies Managing Director, Dr N.G. Vijaya Gopal, said, while lauding the government for its support.
Gopal said the company has already initiated the CE and the US FDA approval process for the devices to expand access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe, and the US.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Lupin launches generic medication in US
Agency: PTI Last Updated: New Delhi, Aug 11 (PTI) Drug maker Lupin on Monday said it has launched a medication, used to regulate blood glucose levels, in the US market. The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement. The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US. PTI MSS DRR DRR First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
2 hours ago
- Mint
Sukino Healthcare eyes upto ₹250 crore VC boost from Bessemer, Jungle Ventures
MUMBAI : Sukino Healthcare is in talks to raise about ₹200–250 crore from venture capital firms including Bessemer Venture Partners and Jungle Ventures, according to three people familiar with the matter. 'The company has appointed Veda Corporate Advisors to help with the fundraise and the transaction is currently undergoing due diligence," the people said. 'The company has grown well in the last 2 years and has been able to prune costs effectively," one of the people cited above said, adding that the VC firms have issued term sheets. Sukino, Veda, Bessemer and Jungle did not respond to Mint's emails sent on Friday afternoon. This fresh round of funding comes more than two years after the Bengaluru-based healthcare startup raised ₹50 crore in its Series A round from Stakeboat Capital in 2023. At the time, the company earmarked the proceeds for expansion into new geographies and technology-led rehabilitation initiatives. Founded in 2015 by Shalini Menon and Rajinish Menon, the company provides home wound care, IV therapy, and other respiratory rehabilitation services. With a presence in Bengaluru, Kochi and Coimbatore, Sukino's other services include continuum care, neuro, cancer and stroke rehabilitation, hydrotherapy rehab, knee and hip replacement among others. The company's investors also include high-net-worth individuals such as Kris Gopalakrishnan, Mohandas Pai, Bhaskar Pramanik, Arihant Patni, Madusudhan Kela and Krishnan Iyer, according to its website. In FY24, Sukino reported revenue of ₹46 crore, up from ₹38.8 crore in FY23, while narrowing its losses to ₹9.5 crore from ₹15.6 crore a year earlier, per Tracxn data. Market intelligence firm Tracxn lists Athulya Senior Care, Geri Care, and Medwell Ventures as Sukino's competitors. Sector outlook The Indian physical rehab market stood at about $17.1 billion in 2023 and is projected to grow at a CAGR of 15.5% in the next 5 years to reach $35 billion by FY28, according to a Redseer report. Growth is expected to be driven by greater rehab adoption amid low awareness, limited provider availability, and capability constraints, said the report. Redseer also highlighted a major gap in geriatric care: over 40% of the elderly population requires rehab services such as caregiving or assisted living, yet only about 6% currently access such services.
Hans India
3 hours ago
- Hans India
Odisha will get 4 new medical colleges: CM
Koraput: Odisha Chief Minister Mohan Charan Majhi on Sunday inaugurated a new building of Shaheed Laxman Nayak Medical College and Hospital in Koraput, expanding its capacity by 650 beds. Majhi also announced that his government will develop a six-lane highway, the Jeypore-Berhampur-Bhubaneswar 'economic corridor'. He said the new building at the hospital has been built at a cost of Rs 280 crore. 'The State government has been making available all facilities at the medical college, so that the people of Koraput and adjoining areas do not have to travel to distant cities for healthcare services,' he said. Majhi said the medical college will benefit the people of Malkangiri, Nabarangpur and Rayagada districts, besides nearby areas of neighbouring Andhra Pradesh and Chhattisgarh. He also said all vacant posts at the medical college would be filled up soon. 'A cancer treatment centre is also being built on 2 acres adjacent to this hospital. For this, our government is spending about Rs 41.15 crore,' he said. The Chief Minister said there are currently 12 government medical colleges in the State, and four more will be set up in Dhenkanal, Bhadrak, Jagatsinghpur and Nabarangpur. A total of 3.46 crore people or 80 per cent of the State's population are getting free healthcare cover under Ayushman Bharat and Gopabandhu Jan Arogya Yojana schemes, he said. 'Till now, about 3.91 lakh people have been provided medical facilities worth Rs 900 crore under these two schemes,' he said. 'Similarly, 8,644 people above 70 have been provided healthcare benefits worth Rs 35.60 crore under Ayushman Vayabandhan Yojana,' he added. Majhi said the people of Koraput will also reap the benefits of development, as a significant amount of work has been accomplished in just one year of the BJP government in the State. Majhi reiterated his government's commitment to make Odisha a leading and prosperous State by 2036, citing progress in education, healthcare, agriculture, industry, employment generation and sustainable economic the function, Health Minister Mukesh Mahaling said another new chapter was added to the history of healthcare services in Koraput with the expansion of the hospital.
